This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
All content for Condensed IP is the property of Randy Noranbrock and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
Aortic Innovations v. Edwards Lifesciences (Fed. Cir., October 27, 2025) 2024-1145
Condensed IP
11 minutes
1 week ago
Aortic Innovations v. Edwards Lifesciences (Fed. Cir., October 27, 2025) 2024-1145
This episode relates to a United States Court of Appeals for the Federal Circuit opinion regarding a patent infringement case, Aortic Innovations LLC v. Edwards Lifesciences Corporation decided October 27, 2025. The core dispute involves the correct claim construction of the term "outer frame" in patents concerning transcatheter aortic valve replacement devices. The Plaintiff-Appellant, Aortic Innovations, appealed a stipulated judgment of non-infringement, which was based on the District Cou...
Condensed IP
This episode regards a United States Court of Appeals for the Federal Circuit opinion, dated October 30, 2025, concerning a patent dispute between Merck Serono S.A. and Hopewell Pharma Ventures, Inc. The case involves Merck's appeal of two consolidated inter partes reviews (IPRs) before the Patent Trial and Appeal Board (Board), which had found certain claims of two Merck patents related to an oral cladribine regimen for treating multiple sclerosis (MS) unpatentable as obvious. The primary le...
